Sign up
Pharma Capital

Motif Bio says two new US patents push exclusivity period over antibiotic out to 2037

The American Patent and Trademark Office has issued what's called a notice of allowance for two patent claims
petrie dish
The company has a market-ready antibiotic

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) said the grant of two US patents pushes its exclusivity over antibiotic iclaprim out to 2037.

It follows what’s called a notice of allowance for patents governing the drug’s use to treat bacterial infections, including acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia and Staphylococcus aureus lung infections in patients with cystic fibrosis. 

WATCH: Motif Bio secures new patents around optimal dose for iclaprim out to 2037

"These US patents provide additional exclusivity for iclaprim in the treatment of bacterial infections well into 2037,” said chief executive Graham Lumsden. 

“We are actively building our intellectual property portfolio in the U.S. and other key markets around the globe."

Having successfully negotiated two Phase III clinical trials, Motif is gearing up to take its next-generation antibiotic to market.

Why Invest In Motif Bio Plc? Read More Here

Register here to be notified of future MTFB Company articles
View full MTFB profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.